Qyuns Therapeutics Co (HKSE:02509) Debt-to-Equity : 1.36 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Qyuns Therapeutics Co Debt-to-Equity?

Qyuns Therapeutics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$203.8 Mil. Qyuns Therapeutics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$335.5 Mil. Qyuns Therapeutics Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$395.8 Mil. Qyuns Therapeutics Co's debt to equity for the quarter that ended in Jun. 2024 was 1.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Qyuns Therapeutics Co's Debt-to-Equity or its related term are showing as below:

HKSE:02509' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.43 Med: 0.82 Max: 2.3
Current: 2.3

During the past 4 years, the highest Debt-to-Equity Ratio of Qyuns Therapeutics Co was 2.30. The lowest was 0.43. And the median was 0.82.

HKSE:02509's Debt-to-Equity is ranked worse than
94.97% of 1014 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:02509: 2.30

Qyuns Therapeutics Co Debt-to-Equity Historical Data

The historical data trend for Qyuns Therapeutics Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qyuns Therapeutics Co Debt-to-Equity Chart

Qyuns Therapeutics Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

0.43

0.46

1.17

2.30

Qyuns Therapeutics Co Quarterly Data
	Dec21	Dec22	Sep23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial			0.46	0.81	1.17	1.36	2.30

Competitive Comparison of Qyuns Therapeutics Co's Debt-to-Equity

For the Biotechnology subindustry, Qyuns Therapeutics Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qyuns Therapeutics Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Qyuns Therapeutics Co's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Qyuns Therapeutics Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Qyuns Therapeutics Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(226.35	+	336.949)	/	244.472
	=	2.30

Qyuns Therapeutics Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(203.767	+	335.503)	/	395.751
	=	1.36

Qyuns Therapeutics Co (HKSE:02509) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Qyuns Therapeutics Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Qyuns Therapeutics Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Qyuns Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qyuns Therapeutics Co Ltd (HKSE:02509) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN

Website

http://www.qyuns.net

Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline.

Executives

Tai Zhou Yi Yao Cheng Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Tai Zhou Jian Xin Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Hang Zhou Zhong Mei Hua Dong Zhi Yao You Xian Gong Si	2101 Beneficial owner
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Ji Shu Chan Ye Tou Zi Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Tai Zhou Yi Yao Gao Xin Qu Hua Yin Jin Rong Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Yuan Da Hua Chuang Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Hua Dong Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Qiu Jiwan
Xu Qiu
Hangzhou Quanyi Investment Management Partnership (general Partnership)
Yu Guo'an
Zhu Jing
Taizhou Xinfu Tongxin Enterprise Management Partnership (limited Partnership)
Sheng Xi Tai

Qyuns Therapeutics Co Headlines

No Headlines